跳至主要内容
临床试验/NCT01332396
NCT01332396已完成不适用

Drug Use Investigation for TYKERB Tablet (All Case Investigation)

Novartis0 个研究点目标入组 4,054 人开始时间: 2009年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Novartis
入组人数
4,054
主要终点
The incidence of adverse events in Japanese patients treated with TYKERB based on prescribing information under the conditions of general clinical practice

研究概览

简要总结

Data on the safety and efficacy of TYKERB shall be collected from the patients in order to grasp the actual conditions of post-marketing use and assess background information on the patients.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with HER2 overexpressing inoperable or recurrent breast cancer

排除标准

  • Patients with hypersensitivity to lapatinib or any components
  • Pregnant women and women suspected of being pregnant

研究组 & 干预措施

Patients prescribed TYKERB

Patients with HER2 overexpressing inoperable or recurrent breast cancer

干预措施: Lapatinib (Drug)

结局指标

主要结局

The incidence of adverse events in Japanese patients treated with TYKERB based on prescribing information under the conditions of general clinical practice

时间窗: 1 year

次要结局

未报告次要终点

研究者

发起方
Novartis
申办方类型
Industry
责任方
Sponsor

相似试验